Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Photo: Scott Eisen/Getty Images
The FDA announced on Monday it has issued an emergency use authorization for Eli Lilly's antibody therapy, bamlanivimab, to treat mild to moderate cases of COVID-19.
Why it matters: The treatment is authorized for people "who are at high risk for progressing to severe COVID-19 and/or hospitalization," including people who are 65 and older, and/or people with certain chronic illnesses.
- "[T]he safety and effectiveness of this investigational therapy continues to be evaluated," the FDA wrote in a news release, but the drug was shown to reduce coronavirus-related hospitalizations or emergency room visits for high-risk patients within 28 days after treatment.
- It's not authorized for people who are already hospitalized or are receiving oxygen.
What they're saying: “As illustrated by today’s action, the FDA remains committed to expediting the development and availability of potential COVID-19 treatments and providing sick patients timely access to new therapies where appropriate, while at the same time supporting research to further evaluate whether they are safe and effective,” said FDA Commissioner Stephen Hahn.
- Eli Lilly Chairman and CEO David Ricks said in a statement, "This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients – adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic."
- Eli Lilly said it would immediately begin shipping bamlanivimab to AmerisourceBergen, which will distribute the drug as directed by the U.S. government's allocation program.
Worth noting: Eli Lilly announced in October that it sold the U.S. government 300,000 vials of bamlanivimab for $375 million, pending the FDA's emergency authorization.
Go deeper: Pfizer says its coronavirus vaccine is more than 90% effective